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Abstract 
The effects of hormonal and dietary stimuli on hepatic glucose and lipid homeostasis in-
clude regulation of gene expression. Berberine, an effective compound in certain Chinese 
medicinal herbs, has been reported to lower plasma glucose and lipid levels in diabetic 
and hypercholesterolemic patients. We hypothesized that it may affect the expression of 
hepatic genes involved in glucose and lipid metabolism. The effects of berberine hydro-
chloride on viability, gene expression, and activation of AMP activated protein kinase 
(AMPK) in primary hepatocytes from Sprague-Dawley (SD), Zucker lean (ZL) or fatty 
(ZF) rats were examined with MTT assay, real-time PCR, and western blotting, respec-
tively. Berberine hydochloride at 50 µM or higher caused cytotoxic effects on hepato-
cytes. In SD and ZL hepatocytes, it induced Gck and suppressed G6pc expression at 10 
and 25 µM, but not as potent as 1 nM insulin. Its effects on Pck1, and insulin-regulated 
Gck and G6pc expression depended on the hepatocyte sources and the dosage used. In ZF 
hepatocytes, it increased Gck, and suppressed Pck1 and G6pc expression without insulin. 
Its effects on Gck and G6pc, but not Pck1 expression, were additive with insulin. Berberine 
hydrochloride  at  25  µM  attenuated  insulin-suppressed  Pck1  (ZL/ZF  cells),  and  insu-
lin-induced Srebp-1c expression (SD/ZL/ZF cells), suggesting modulation of insulin ac-
tion. Berberine hydrochloride did not alter these genes’ mRNA stability. Its treatment 
caused a dose-dependent increase of phosphorylation of AMPKα, and its substrate, ace-
tyl-CoA carboxylase, in primary hepatocytes. We conclude that berberine hydrochloride 
regulated the transcription of hepatic genes involved in glucose and fatty acid metabo-
lism. 
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Introduction 
The increased rate of metabolic diseases, such as 
obesity, diabetes and cardiovascular disease, has be-
come a major public health concern (1). The common 
characteristic of human obesity and type 2 diabetes is 
insulin  resistance  (2).  It  has  been  shown  that  tight 
blood glucose control is helpful to reduce the risk of 
cardiovascular disease, a leading cause of death for 
patients with diabetes (3). Liver plays a critical role in 
mediating glucose and lipid homeostasis regulated by 
hormones  and  nutrients.  In  liver  and  hepatocytes, 
insulin stimulates or inhibits the expression of a vari-
ety of genes responsible for glycolysis, glycogenesis 
and lipogenesis, and inhibits gluconeogenesis (4). This 
insulin-regulated hepatic gene expression, at least in 
part, is responsible for the control of glucose and lipid 
homeostasis (5,6).  
For hepatic glucose metabolism, insulin increas-
es the expression of glucokinase gene (Gck) (7,8), the 
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enzyme responsible for the first step of hepatic glu-
cose  utilization.  It  suppresses  the  expression  of  the 
cytosolic  form  of  phosphoenolpyruvate  carboxyki-
nase  (Pck1)  (9)  and  glucose  6-phosphatase  catalytic 
subunit (G6pc) (4), the first and last steps of glucone-
ogenesis, respectively. For hepatic lipid metabolism, 
insulin increases the expression levels of sterol regu-
latory element binding protein 1c gene (Srebp-1c) (10). 
Sterol regulatory element-binding proteins (SREBPs) 
are critical transcription activators for hepatic choles-
terol and fatty acid biosynthesis, and their homeosta-
sis (11). Therefore, any nutritional or pharmacological 
factor  that  alters  the  expression  of  these  insu-
lin-regulated genes will have the potential to modu-
late or regulate the hepatic glucose and lipid homeo-
stasis.  
Berberine is an isoquinoline alkaloid of the pro-
toberberine type, which is found in many plant spe-
cies such as Coptis Chinensis Franch used in tradi-
tional Chinese medicine. Because of its antimicrobial 
activity, it has been used conventionally for treatment 
of  diarrhea  (12).  Recently,  it  has  been  shown  that 
berberine  has  anti-diabetic  effects  in  experimental 
animals and clinical diabetic patients (13-16). It low-
ered plasma glucose as effectively as metformin (17), a 
widely prescribed medicine for the treatment of type 2 
diabetes.  Multiple  mechanisms  of  berberine  actions 
have  been  proposed  such  as  increase  of  glycolysis 
(18),  insulin  secretion  (14),  and  insulin  receptor  ex-
pression level (17), etc. Recently, it has been shown 
that berberine activates AMP-activated protein kinase 
(AMPK) (13,19), a pathway activated by metformin as 
well (20). In addition, berberine has been shown to 
reduce  low  density  lipoprotein  cholesterol  by 
up-regulating  LDL  receptor  mRNA  expression  (21). 
This  hypolipidemic  effect  of  berberine  has  been  at-
tributed to its ability to activate AMPK (22). Recently, 
it has been shown that berberine treatment inhibited 
hepatic  gluconeogenesis  in  rats  of  an  insu-
lin-insufficient type 2 diabetic model. This has been 
attributed  to  berberine-mediated  inhibition  of  Pck1 
and  G6pc  expression  in  an  insulin-independent 
pathway  (23).  We  hypothesize  that  the  beneficiary 
effects of berberine on glucose and lipid metabolism 
may derive from its direct effects on the expression of 
hepatic  genes  involved.  Since  insulin  also  regulates 
the expression levels of many of them, we envision 
that berberine may have the potential to affect insulin 
action as well. 
Herein,  we  examined  the  effects  of  berberine 
hydrochloride on the expression of insulin-regulated 
representative genes, Gck, Pck1, G6pc and Srebp-1c in 
primary  hepatocytes  from  normal  Sprague-Dawley 
(SD), Zucker lean (ZL) or Zucker fatty (ZF) rats. Both 
ZL and ZF rats have been widely used as rat models 
for the development of obesity, insulin resistance and 
other aspects  of metabolic diseases  (24,25). We also 
examined  the  effects  of  berberine  hydrochloride  on 
AMPK activation in primary hepatocytes.  
Materials and methods 
Reagent:  Berberine  hydrochloride  was  pur-
chased  from  National  Institutes  for  Food  and  Drug 
Control  (>  97.9  %,  Beijing,  China).  Methylthiazol-
yldiphenyltetrazolium bromide (MTT) was obtained 
from  Sigma  (Saint  Louis,  MO).  Antibodies  to  phos-
pho-AMPKα  (Thr172),  total  AMPKα,  phospho-Akt 
(Ser473), total Akt, phospho-acetyl-CoA carboxylase 
(Ser79),  total  acetyl-CoA  carboxylase  (ACC),  and 
β-actin, were obtained from Cell Signaling Technolo-
gies  (Danvers,  MA).  Other  reagents  have  been  de-
scribed previously (26).  
Animal and hepatocytes: Male Sprague-Dawley 
or Zucker rats were purchased from Harlan Breeders 
(Indianapolis, IN) or bred in the Department of Nu-
trition at the University of Tennessee at Knoxville. All 
experimental  procedures  were  approved  by  the  In-
stitutional Animal Care and Use Committee. All the 
guidelines for the use and care of laboratory animals 
were followed. 
Primary  hepatocytes  were  isolated  from 
non-fasted male SD (10 to 14 weeks), ZL or ZF (9 to 11 
weeks of ages) rats, and seeded as described (26). Af-
ter attachment, hepatocytes were washed once with 3 
ml of PBS, and incubated in medium A (Medium 199 
containing 100 nM dexamethasone, 100 nM T3, 100 
U/ml sodium penicillin and 100 μg/ml streptomycin 
sulfate) with 1 nM insulin for overnight at 37°C and in 
5% CO2. The hepatocytes were treated as indicated in 
the  figure  legends  before  the  total  RNA  or  protein 
were  extracted  for  real-time  PCR  or  Immunoblot 
analysis, respectively. 
MTT  (3-(4,5-Dimethylthiazol-2-yl)-2,5-dip-
henyltetrazolium bromide) based Cell viability as-
say: Primary hepatocytes from ZL rats were washed 
once  with  3  ml  PBS  and  incubated  in  medium  A 
without or with increasing concentrations of berber-
ine hydrochloride in the absence or presence of 1 nM 
insulin for 4 h. After which, 20 μl MTT (5 mg/ml) was 
added to each well, and the cells were incubated for 
additional 4h. After removal of the medium, forma-
zan crystal formed inside the cells was dissolved in 
150 μl DMSO. The absorbance at 490 nm was meas-
ured  using  a  Packard  Spectra  Count  plate  reader 
(Model#: 851).  
Total  RNA  isolation,  cDNA  synthesis  and 
quantitative real time PCR:  Total RNA was isolated 
using  the  RNA  STAT-60
TM  reagent  (TEL-TEST,  Inc, Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
675 
Friendswood,  TX)  according  to  the  protocol.  The 
procedures  for  cDNA  synthesis  and  real  time  PCR 
have  been  described  previously  (26).  The  relative 
amounts of mRNAs except for Fig. 3 were calculated 
using  the  comparative  CT  method  as  described  (26) 
with 36B4 as the invariant control gene.  
RNA  stability  assay:  For  RNA  stability  assay, 
primary hepatocytes were washed once with 3 ml PBS 
and incubated in medium A without or with 3 μM 
α-amanitin in the absence or presence of 25 μM ber-
berine hydrochloride. Total RNAs were isolated at 0.5, 
1, 2, 4, and 6 h, and subjected to real-time PCR analy-
sis. The relative amounts of indicated transcripts were 
calculated  using  the  method  as  described  (26).  The 
level  of  each  transcript  at  time  0  were  assigned  as 
100%. 
Immunoblot  analysis.  After  indicated  treat-
ments in the figure legends, primary hepatocytes in a 
60 mm dish were washed once with 3 ml PBS and 
scrapped from the dish in 400 µl of whole-cell lysis 
buffer (1% Triton X-100, 10% glycerol, 1.0% IGEPAL 
CA-630, 50 mM Hepes, 100 mM NaF, 10 mM EDTA, 5 
mM Sodium orthovanadate, 1.9 mg/ml aprotinin, 5 
µg/ml leupeptin, 1 mM Benzamide, 2.5 mM DMSF, 
pH 8.0). The lysates were allowed to sit on ice for at 
least 20 minutes before subjected to 20,000×g centrif-
ugation  for  20  minutes.  The  protein  content  in  the 
supernatant was determined with PIERCE BCA pro-
tein assay kit (Rockford, IL). Proteins (30 µg/lane) in 
whole  cell  lysates  were  separated  on  SDS/PAGE, 
transferred  to  BIO-RAD  Immuno-Blot  PVDF  mem-
brane (Hercules, CA), and detected with primary an-
tibodies according to the protocols provided by the 
manufacturers. Bound primary antibodies were visu-
alized by chemiluminescence (ECL Western Blotting 
Substrate; Thermo Scientific) using a 1:5,000 dilution 
of goat anti-rabbit IgG (Upstate) conjugated to horse-
radish peroxidase. Filters were exposed to X-ray films 
(Phenix Research Products, Candler, NC) for protein 
band detection. 
Statistics.  Data are presented as means ± S.D. 
The  number  of  experiments  represents  the  inde-
pendent experiments using hepatocytes isolated from 
different animals on different days. Levene’s test was 
used to determined homogeneity of variance among 
groups using SPSS 19.0 statistical software and where 
necessary natural log transformation was performed 
before  analysis.  An  independent-samples  t-test  was 
used to compare two conditions. Multiple compari-
sons were analyzed by one-way ANOVA using least 
significant different (LSD) when equal variance was 
assumed,  and  Games-Howell  test  was  used  when 
equal  variance  was  not  assumed.  Differences  were 
considered statistically significant at P < 0.05. 
Results 
The effects of berberine hydrochloride on via-
bility of primary hepatocytes from SD rats. To de-
termine any cytotoxic effect, the viabilities of primary 
hepatocytes treated with increasing concentrations of 
berberine  hydrochloride  was  measured  with  MTT 
assay  as  shown  in  Fig.  1.  The  viabilities  of  the 
hepatocytes treated with 1 to 25 μM of berberine hy-
drochloride were not significantly different from that 
of the control group without or with insulin. Howev-
er, berberine hydrochloride at 50 or 100 µM reduced 
the viabilities to 70.7% or 60.7% (without insulin), and 
78.5% or 52.0% (with insulin), respectively. These re-
sults demonstrated that berberine hydrochloride up 
to 25 µM can be used to treat rat primary hepatocytes 
without the concern of cytotoxic effects in the current 
experimental settings. 
 
 
 
Fig. 1. The effects of berberine hydrochloride on via-
bility of primary hepatocytes from SD rats. The primary 
hepatocytes from SD rats were first incubated in medium 
A without or with berberine hydrochloride (1 to 100 μM) 
for 4 hours in the absence or present of 1 nM insulin. 
After this pre-incubation, MTT was added for additional 
4 hours before hepatocyte viabilities were determined 
as described in the Materials and Methods section. The 
OD value in control group without insulin was arbitrarily 
assigned as 100%. Results represented means ± SD of six 
experiments (* P < 0.01, for comparing the values of 
control with the values of the indicated treatments).  
 
 
The effects of berberine hydrochloride on the 
expression  of  Gck,  G6pc,  Pck1  and  Srebp-1c  in 
hepatocytes from SD rats. Fig. 2A-D showed the rel-
ative expression levels of Gck, G6pc, Pck1 and Srebp-1c Int. J. Biol. Sci. 2011, 7 
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transcripts  in  SD  primary  hepatocytes  treated  with 
vehicle  control  or  increasing  concentrations  of  ber-
berine  hydrochloride  in  the  absence  or  presence  of 
insulin. Berberine hydrochloride alone at  10 and 25 
μM significantly induced the expression of Gck by 3.4 
± 1.1-fold and 5.0 ± 2.5 -fold, respectively (Fig. 2A). 
Insulin induced Gck expression at all concentrations of 
berberine  hydrochloride  as  expected.  However,  no 
additive effect was observed between them. Fig.  2B 
showed  that  10  or  25  μM  berberine  hydrochloride 
alone significantly reduced G6pc mRNA to 0.41 ± 0.18 
or 0.14 ± 0.04 -fold of the control value, respectively. 
Fig. 2C showed that 25 μM berberine hydrochloride 
reduced the Pck1 expression level to 0.50 ± 0.03 -fold 
of its value of the control group in the absence of in-
sulin  (P<0.01).  Insulin  significantly  reduced  the  ex-
pression levels of G6pc and Pck1 as expected. How-
ever,  berberine  hydrochloride  could  not  further  re-
duce insulin-suppressed G6pc or Pck1 expression. Fig. 
2D showed that  25 μM berberine hydrochloride in-
duced  the  expression  of  Srebp-1c  by  5.9  ±  2.0-fold 
(P<0.05) in the absence of insulin. Surprisingly, this 
concentration of berberine hydrochloride attenuated 
insulin-induced  Srebp-1c  expression,  which  was  not 
affected by other concentrations of berberine hydro-
chloride tested.  
 
 
Fig. 2. The effects of berberine hydrochloride on the levels of Gck (A), G6pc (B), Pck1 (C) and Srebp-1c (D) transcripts 
in hepatocytes from SD rat. Primary hepatocytes were treated with either vehicle or berberine hydrochloride (1 to 25 
μM) for 6h in the absence or present of 1 nM insulin. The expression levels of indicated transcripts were analyzed using 
real-time PCR. The expression level in control group without insulin was arbitrarily assigned as 1. Results represented 
means ± SD of three independent experiments (* for comparing the fold induction of the indicated transcript at the 
berberine hydrochloride concentration in the absence with that in the presence of insulin; for Gck, b>a; for G6pc, 
d/e>g, c/d/e>h, d’>f’/g’/h’, and e’>g’; for Pck1, n>i/j/k; for Srebp1c, t>s>o/p/q, t>r, and t’>o’/p’/q’/r’/s’; all 
P<0.05). Int. J. Biol. Sci. 2011, 7 
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Fig. 3. The effects of berberine hydrochloride on the stabilities of 36B4 (A), Gck (B), G6pc (C), Pck1 (D) and Srebp-1c 
(E) transcripts. ZL rat primary hepatocytes were treated with medium A containing 3 μM α-amanitin in the absence or 
present of 25 µM berberine hydrochloride. Total RNAs were extracted at 0.5, 1, 2, 4 and 6 h after treatment, and 
subjected to real-time PCR analysis. The amount of indicated gene transcripts at time 0 was arbitrarily assigned as 
100%. Results represented means ± SD of three independent experiments.  
 
 
The effects of berberine hydrochloride on the 
stabilities of  Gck, G6pc, Pck1 and Srebp-1c in pri-
mary hepatocytes from ZL rats. We next determined 
whether the change of the gene expression levels was 
caused by alteration of transcription or stability of the 
transcripts. The stabilities of the Gck, G6pc, Pck1 and 
Srebp-1c  mRNA  were  measured  in  the  presence  of 
α-amanitin, a specific inhibitor of RNA polymerase II 
complex (27). As shown in Fig.  3A, the contents  of 
36B4 transcripts exhibited no difference between the 
vehicle  control  and  25  µM  berberine  hydrochloride 
groups.  Fig.  3B-E  respectively  showed  the  decay  of 
Gck, G6pc, Pck1 and Srebp-1c transcripts in the absence 
or presence of berberine hydrochloride. At 0.5, 1, 2, 4, 
and  6  h  after  α-amanitin  treatment,  the  contents  of 
indicated  transcripts  in  the  berberine  hydrochloride 
group were not significant different from those in the 
control groups of the corresponding genes, indicating 
no  effect  of  berberine  hydrochloride  on  the  decay 
rates  of  those  transcripts.  The  estimated  half  life  of 
Gck, G6pc, Pck1 or Srebp-1c transcripts was about 1.5h, 
3h, 4h or 6h for either control or berberine hydrochlo-
ride  group,  respectively.  It  indicated  that  berberine 
hydrochloride  regulated  the  transcription  of  Gck, 
G6pc, Pck1 and Srebp-1c in primary rat hepatocytes. 
The effects of berberine hydrochlorides on the 
expression levels of Gck, G6pc, Pck1 and Srebp-1c in 
primary hepatocytes from ZL rats. To determine the 
berberine hydrochloride effects on gene expression in 
hepatocytes derived from a difference strain of rats, 
hepatocytes  were  isolated  from  ZL  rats,  which  are 
insulin sensitive and have been used as controls for 
insulin resistant ZF rats (24,25). The expression levels 
of  Gck,  G6pc,  Pck1  and  Srebp-1c  in  ZL  hepatocytes 
treated  with  increasing  concentrations  of  berberine 
hydrochloride (0 to 25 µM) in the absence or presence 
of insulin were analyzed as shown in Fig. 4. Berberine 
hydrochloride started to significantly induce Gck ex-
pression by 1.6 ± 0.4-fold at 5 μM in the absence of 
insulin  (Fig.  4A).  Insulin  significantly  induced  Gck 
expression at all berberine hydrochloride concentra-
tions  tested.  However,  there  was  an  attenuation  of 
insulin-induced  Gck  expression  when  berberine  hy-
drochloride  was  at  25  µM,  a  phenomenon  not  ob-
served in SD hepatocytes. For G6pc, 10 or 25 μM ber-
berine hydrochloride alone respectively reduced G6pc Int. J. Biol. Sci. 2011, 7 
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mRNA to  0.3 ± 0.1 or 0.5 ±  0.3 -fold of the control 
value in the absence of insulin (Fig. 4B). Interestingly, 
10 µM or 25 µM berberine hydrochloride respectively 
potentiated  or  attenuated  insulin-suppressed  G6pc 
expression, a difference with SD hepatocytes. Fig. 4C 
showed that 25 μM berberine hydrochloride signifi-
cantly attenuated insulin-suppressed Pck1 expression, 
but had no effects on its expression in the absence of 
insulin,  a  difference  with  SD  hepatocytes.  The  ex-
pression  levels  of  G6pc  and  Pck1  mRNA  in  control 
group was not significantly different from that of in-
sulin group when berberine hydrochloride was at 25 
µM, suggesting attenuation of insulin-mediated sup-
pression of these two genes. Fig. 4D showed that in 
ZL hepatocytes, berberine hydrochloride up to 25 μM 
did not affect the expression of Srebp-1c without insu-
lin,  a  difference  with  SD  hepatocytes.  Insulin  no 
longer  induced  Srebp-1c  when  berberine  hydrochlo-
ride concentration was 25 µM, a similar phenomenon 
in SD hepatocytes.  
 
 
 
 
Fig. 4. The effects of berberine hydrochloride on the levels of Gck (A), G6pc (B), Pck1 (C) and Srebp-1c (D) transcripts 
in hepatocytes from Zucker lean rat. Primary hepatocytes from ZL rats were treated with either vehicle or berberine 
hydrochloride (2.5 to 25 μM) for 6h in the absence or present of 1 nM insulin. Total RNAs were extracted and subjected 
to real-time PCR analysis. The gene expression level in control group without insulin was arbitrarily assigned as 1. 
Results represented means ± SD of four independent experiments (* for comparing the fold induction of the indicated 
transcript at the berberine hydrochloride concentration in the absence with that in the presence of insulin; for Gck, 
e>c>a, d/e>a/c, a’>c’/d’>e’; for G6pc, f/g/h>i/j, and j’>f’/g’/h’>i’; for Pck1, l>k; for Srebp1c, m>n; all P<0.05). Int. J. Biol. Sci. 2011, 7 
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Fig. 5. The effects of berberine hydrochloride on the levels of Gck (A), G6pc (B), Pck1 (C) and Srebp-1c (D) in 
hepatocytes from Zucker fatty rat. Primary hepatocytes from ZF rats were treated with either vehicle or berberine 
hydrochloride (1 to 25 μM) for 6h in the absence or present of 1 nM insulin. Total RNAs were extracted and subjected 
to real-time PCR analysis. The gene expression level in control group without insulin was arbitrarily assigned as 1. 
Results represented means ± SD of three independent experiments (* for comparing the fold induction of the indi-
cated transcript at the berberine hydrochloride concentration in the absence with that in the presence of insulin; for 
Gck, f>d>a, e>a, e/f>b, d’/e’>a’/b’; for G6pc, g>i>k, g>j/l, h>j/k/l, and g’/h’>i’/k’/l’; for Pck1, m>n/r>p/q, and 
m>o; all P<0.05). 
 
 
The effects of berberine hydrochlorides on the 
expression levels of Gck, G6pc, Pck1 and Srebp-1c in 
primary hepatocytes from ZF rats. To determine the 
berberine  effects  on  gene  expression  in  hepatocytes 
from  insulin  resistant  animals,  we  used  primary 
hepatocytes from obese and insulin resistant ZF rats 
(24,25).  Fig.  5A-D  respectively  showed  the  relative 
expression  levels  of  Gck,  G6pc,  Pck1  and  Srebp-1c 
transcripts  in  ZF  primary  hepatocytes  treated  with 
vehicle  control  or  increasing  concentrations  of  ber-
berine hydrochloride in the absence or presence of 1 
nM insulin. In the absence of insulin, berberine hy-
drochloride at 5 μM started to induce Gck expression 
by 1.9 ± 0.5-fold (Fig. 5A). Insulin induced the level of 
Gck transcript to 6.5 ± 1.0- fold of the control value in 
the  absence  of  berberine  hydrochloride.  Berberine 
hydrochloride at 5 and 10 μM significantly potenti-
ated insulin-induced expression of Gck, suggesting an 
additive  effect  between  insulin  and  these  two  con-
centrations  of  berberine  on  Gck  expression  in  ZF 
hepatocytes.  Fig.  5B  and  5C  showed  that  berberine 
hydrochloride alone at 2.5 and 1 µM started to signif-
icantly  suppress  G6pc  and  Pck1  expression  in  ZF 
hepatocytes, respectively. The levels of G6pc and Pck1 
transcripts  in  10  µM  berberine  hydrochloride  treat-
ment group reached 0.11 ± 0.01- and 0.32 ± 0.02-fold of 
the control value, respectively. Interestingly, the Pck1 
expression  levels  in  25  µM  treatment  group  were 
higher than those in 5 and 10 µM berberine hydro-
chloride  groups  (Fig.  5C).  Insulin  respectively  re-
duced the levels of G6pc and Pck1 transcript to 0.35 ± 
0.07- and 0.25 ± 0.03-fold of the control value. In the Int. J. Biol. Sci. 2011, 7 
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presence of 1 nM insulin, berberine hydrochloride at 
2.5 to 25 μM further reduced the expression levels of 
G6pc transcript, but not Pck1, in ZF hepatocytes. The 
effects of berberine hydrochloride on the expression 
of Srebp-1c in hepatocytes from ZF rats were weak at 
the most. Fig. 5D showed that berberine hydrochlo-
ride did not significantly affect Srebp-1c expression in 
the absence of insulin. Insulin only slightly induced 
Srebp-1c  expression  in  fatty  hepatocytes.  This  weak 
induction  no  longer  existed  when  berberine  hydro-
chloride was at 5 µM or higher, suggesting attenua-
tion  of  insulin-induced  Srebp-1c  expression  by  ber-
berine treatment in ZF hepatocytes.  
Berberine  hydrochloride  activated  AMPK  in 
primary  hepatocytes.  Fig.  6  showed  that  berberine 
hydrochloride treatment started to cause phosphory-
lation of AMPKα subunits at threonine 172 as low as 3 
µM  in  ZL  hepatocytes.  This  phosphorylation  of 
AMPK correlated with an induction of phosphoryla-
tion of its substrate, ACC, at serine 79 in the absence 
or presence of 1 nM insulin. It demonstrated an in-
crease of AMPK activity after berberine hydrochloride 
treatment. Insulin treatment resulted in phosphoryla-
tion of its downstream signaling target, Akt at serine 
473, demonstrating the activation of insulin signaling 
transduction  pathway.  There  are  no  significant 
changes of total AMPKα, ACC, Akt, and β-actin in the 
same hepatocytes treated without and with berberine 
hydrochloride in the absence or presence of insulin.  
 
 
Fig. 6. Immunoblot analysis of phosphor-AMPKα, total AMPKα, phosphor-ACC, total ACC, phosphor-Akt, total Akt, and 
β-actin in primary hepatocyes treated with berberine hydrochloride in the absence or presence of insulin. After 
overnight pretreatment, primary hepatocytes from Zucker lean rats were incubated in medium A without or with 
increasing concentrations of berberine hydrochloride (1 to 30 µM) in the absence or presence of 1 nM insulin for 20 
minutes. Total protein (30 µg/lane) was separated on SDS/PAGE, detected by specific primary antibodies as indi-
cated, and visualized by chemiluminescence. Graph was the representative of three independent experiments with 
similar results using hepatocytes isolated from three different ZL rats in three different days. 
 
 
Discussion  
In this study, we reported the effects of berberine 
hydrochloride on the expression of hepatic genes in-
volved in glucose and lipid metabolism. It has been 
reported that berberine administrated orally was well 
tolerated in rodents (100 to 300 mg/kg) and human 
(500 mg two to three times per day/person) (13-16). 
The dosages used here were similar to the concentra-
tions used (5 to 15 µg/ml which are equivalent to 15 to 
45  µM)  in  previous  reports  showing  activation  of 
signal transduction pathways (13) and regulation of 
gene expression (21). Our results demonstrated that 
25 µM berberine hydrochloride was well tolerated by 
primary hepatocytes in the current experimental set-
tings (Fig. 1). The observed cytotoxic effect of 50 or 
100  µM  berberine  hydrochloride  was  reasonable  as 
berberine and its derivatives inhibited activity of mi-Int. J. Biol. Sci. 2011, 7 
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tochondrial complex I of electron transport chain (28). 
The tolerance of berberine in the in vivo studies may 
be  attributed  to  its  poor  bioavailability  due  to  the 
P-glycoprotein  on  small  intestine,  which  actively 
pumps berberine back into the intestinal lumen (29). 
This might have prevented higher concentrations of 
berberine in plasma and exerted toxic effects on liver. 
Recently, some attempts have been taken to modify 
the structure of berberine and identify its analogues 
for the improvement of its bioavailability and efficacy 
(28,30-33). Whether any of those derivatives and ana-
logues  has  the  same  effects  on  viability  of  primary 
hepatocytes  remains  to  be  seen.  In  addition,  how 
berberine  and  its  derivatives  are  transported  and 
catabolized in primary hepatocytes also deserves to be 
investigated.  Nevertheless,  the  results  shown  here 
have provided a reference for future berberine studies 
in primary hepatocytes. 
We initiated our studies using hepatocytes from 
SD rats and observed the effects of berberine hydro-
chloride on gene expression in them (Fig. 2). Subse-
quently, we decided to examine berberine effects on 
hepatocytes  in  insulin  resistant  Zucker  fatty  rats. 
Therefore, we conducted similar dosage experiments 
in hepatocytes (Fig. 4) from ZL rats which are insulin 
sensitive and have been used as the controls for obese 
and  insulin  resistant  ZF  rats  (24,25).  In  hepatocytes 
from both SD and ZL rats, berberine hydrochloride at 
10  and  25  µM  increased  Gck,  and  suppressed  G6pc 
expression  in  the  absence  of  insulin.  However,  the 
magnitude of the induction or suppression was not 
the same as that mediated by insulin (Fig. 2 and 4). In 
hepatocytes from either SD or ZL rats, berberine hy-
drochloride  at  25  µM  attenuated  insulin-induced 
Srebp-1c  expression.  Nevertheless,  the  hepatocytes 
from  these  two  strains  of  rats  showed  some  differ-
ences regarding the responses of these genes to ber-
berine  hydrochloride  treatments.  For  Gck,  berberine 
hydrochloride at 25 µM attenuated insulin-induced its 
expression in ZL, but not SD hepatocytes. The same 
treatment reversed berberine hydrochloride- and in-
sulin-suppressed G6pc expression to a certain extent 
in ZL, but not in SD hepatocytes. For Pck1, berberine 
hydrochloride at 25 µM reduced its expression in SD, 
but not in ZL hepaotcytes in the absence of insulin. In 
the  presence  of  insulin,  it  only  attenuated  insu-
lin-suppressed Pck1 expression in ZL, but not in SD 
hepatocytes.  Berberine  hydrochloride  started  to  in-
duce Srebp-1c expression at 10 µM in SD, but not ZL in 
hepatocytes. All these results demonstrated that ber-
berine hydrochloride had the ability to regulate the 
expression  of  these  four  insulin-regulated  genes  in 
primary hepatocytes. The regulation can be masked 
by insulin treatment (such as Gck and G6pc). On the 
other hand, berberine hydrochloride can modify in-
sulin’s  action  on  the  expression  of  its  downstream 
target gene (such as Srebp-1c). In addition, some of the 
effects on a particular gene expression (such as Pck1) 
may  depend  on  the  strain  of  rats  from  which  the 
hepatocytes were obtained.  
The  fact  that  berberine  hydrochloride  did  not 
change the mRNA stabilities of these four genes (Fig. 
3)  indicated  that  it  regulated  their  transcription  in 
primary hepatocytes, which is also regulated by insu-
lin. In the process of submitting our current manu-
script, a report came out and demonstrated that ber-
berine inhibited hepatic Pck1 and G6pc expression in 
an  insulin-independent  pathway  (23).  Our  results 
showed  that  berberine  directly  regulated  these  two 
genes’ transcription, which is in agreement with their 
observations. In addition, we also demonstrated that 
berberine can induce the expression of Gck, suggest-
ing glucose usage as another target of berberine action 
in  liver.  It  has  been  shown  the  metformin,  another 
reagent  that  activates  AMPK  (20),  and  insulin  sup-
pressed  hepatic  Pck1  and  G6pc  expression  through 
phosphorylation of CREB binding protein (34). Both 
metformin and insulin treatments caused activation of 
PKCι/λ  via  activation  of  AMPK  and  phosphoinosi-
tide-dependent protein kinase 1 (PDK1), respectively. 
However, only insulin activates Akt/PKB, and met-
formin activates AMPK (34). It indicated that activa-
tion metformin and insulin shared a common signal 
transduction pathway. Given the effects of berberine 
hydrochloride  on  Gck,  Pck1  and  G6pc  expression,  it 
seems that insulin and berberine activated a common 
signaling  pathway  that  leads  to  regulation  of  these 
genes’  transcription  in  primary  rat  hepatocytes. 
However, given the effects of berberine hydrochloride 
on Srebp-1c expression in the presence of insulin, it 
seems  that  berberine  antagonized  part  of  insu-
lin-regulated gene expression. It has been shown that 
insulin-mediated induction of Srebp-1c expression and 
suppression of  Pck1 expression bifurcated at mTOR 
step, which is downstream of PDK1 activation  (35). 
Berberine  hydrochloride  treatment  might  have  acti-
vated part of insulin-mediated pathways involved in 
glucose metabolism and antagonized insulin-induced 
Srebp-1c expression. Whether the berberine signaling 
in hepatocytes shares part of insulin pathways or ini-
tiates a novel pathway deserves further investigation.  
The beneficial effects of berberine on type 2 dia-
betes and insulin resistance subjects (13-16) indicated 
that it may have effects on hepatocytes isolated from 
insulin resistant fatty rats. In a different manuscript, 
we have reported that the insulin-regulated gene ex-
pression in ZF hepatocytes was impaired or dimin-
ished when compared to that in ZL hepatocytes. Our Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
682 
results shown here also supported this claim when the 
fold  inductions  of  these  four  genes  in  ZL  and  ZF 
hepatocytes were compared (Fig. 4 and  Fig. 5). We 
showed here that berberine hydrochloride increased 
Gck expression in fatty hepatocytes as it did in SD and 
ZL hepatocytes (Fig. 4 and Fig. 5). The difference here 
is that berberine and insulin had additive effects on 
the induction of Gck expression in fatty hepatocytes, 
but not in SD or ZL cells. For G6pc expression, ber-
berine suppressed its expression in ZF hepatocytes as 
low as 2.5 µM, a concentration that could not affect 
G6pc expression in SD and ZL hepatocytes. In addi-
tion,  berberine  potentiated  insulin-suppressed  G6pc 
expression at concentration as low as 2.5 µM. For Pck1 
expression  in  ZF  hepatocytes,  berberine  suppressed 
its expression levels in the absence of insulin at con-
centration as low as 1 µM, which was not observed in 
SD or ZL hepatocytes. Unlike its effects on G6pc ex-
pression,  berberine  did  not  potentiated  insu-
lin-suppressed Pck1 expression. For Srebp-1c, berber-
ine hydrochloride had almost no effect on its expres-
sion in fatty hepatocytes without or with insulin. The 
unresponsiveness of Srebp-1c to berberine hydrochlo-
ride treatment in fatty hepatocytes could be caused by 
the elevated expression of Srebp-1c (36) or alteration of 
the mechanisms of its regulation in fatty hepatocytes. 
These results indicated that the expression levels of 
Gck, G6pc and Pck1 were more sensitive to berberine 
treatment  in  ZF  hepatocytes  than  in  SD  or  ZL 
hepatocytes.  In  addition,  insulin-regulated  Gck  and 
G6Pc  can  be  modified  in  the  presence  of  berberine 
hydrochloride  (5  and  10  µM),  suggesting  improve-
ment of insulin action. Whether the pre-existence of 
insulin resistance in the ZF hepatocytes plays a role 
here or not deserves further study. 
Our results demonstrated that berberine hydro-
chloride dose-dependently induced phosphorylation 
of AMPKα in primary hepatocytes  without or with 
insulin. The phosphorylation of AMPKα in primary 
hepatocytes correlated with an increase of the phos-
phorylation of its substrate ACC, demonstrating the 
elevation  of  AMPK  activity  after  berberine  hydro-
chloride  treatment  in  primary  hepatocytes  (Fig.  6). 
This  activation  of  AMPK  was  not  affected  by  the 
presence of insulin, which induces phosphorylation of 
Akt, a downstream kinase mediating insulin signaling 
pathway. It has been shown that berberine activated 
AMPK in 3T3-L1 adipocytes (13) and in L6 myotubes 
(37).  Constitute  activation  of  AMPK  in  mouse  liver 
reduced Srebp-1c expression (38). This AMPK activa-
tion mediated by berberine hydrochloride treatment 
might  have  contributed  to  the  attenuation  of  insu-
lin-induced  Srebp-1c  expression  in  the  presence  of 
berberine hydrochloride (Fig. 2, 4 and 5). Reduction of 
plasma  triglyceride  and  cholesterol  levels  were  ob-
served in hypercholesterolemic patients treated with 
berberine (21). Given the critical role of SREBP-1c in 
hepatic  lipogenesis  (11),  this  antagonization  of  ber-
berine hydrochloride to insulin-induced Srebp-1c ex-
pression might have contributed to the hypolipidemic 
effects of berberine. However, it is worth to note that 
in ZL hepatocytes, berberine hydrochloride at 10 and 
25 µM potentiated and attenuated insulin-suppressed 
G6pc  expression,  respectively  (Fig.  4).  One  explana-
tion  is  that  the  degree  of  AMPKα  phosphorylation 
might have played a role here. As shown in Fig. 6, 
phosphorylation  of  AMPKα  was  further  enhanced 
with  the  rise  of  berberine  hydrochloride  concentra-
tions from 10 µM to 30 µM. The additional phosphor-
ylation of AMPKα might have changed the dynamic 
of AMPK activation,  which might have contributed 
negatively to insulin’s effects on G6pc expression. It 
has been reported that AMPK phosphorylated raptor, 
a component of mTORC1 complex. This phosphory-
lation resulted in suppression of its activity, which is 
responsible  for  the  inhibition  of  mTORC1  and 
cell-cycle arrest induced by energy stress (39). Alter-
natively, another signaling pathway might have been 
activated  by  25  µM  berberine  hydrochloride,  which 
might have contributed to the phenomenon. The ac-
tivation of AMPK alone may not be enough to explain 
all  the  berberine  hydrochloride  effects.  It  has  been 
shown that metformin, another antidiabetic drug that 
can activate AMPK (20), still suppressed hepatic glu-
coneogenesis in mice without AMPK catalytic subu-
nits  (AMPKα  knockout)  (40).  Given  the  different 
functions  of  these  four  genes  in  glucose  and  lipid 
metabolism, it is possible that AMPK activation may 
not be the only reason for the observed effects of ber-
berine  on  these  four  genes’  expression  in  primary 
hepatocytes.  The  mechanisms  by  which  berberine 
hydrochloride  affect  hepatic  genes  involved  in  glu-
cose metabolism remain to be investigated.  
In  summary,  we  demonstrated  that  berberine 
hydrochloride  regulated  the  transcription  of  repre-
sentative  genes  involved  in  glucose  and  fatty  acid 
synthesis in hepatocytes from either insulin sensitive 
rats (SD and FL) or resistant (ZF) rats. It suggests that 
the  beneficial  effects  of  berberine  on  diabetes  and 
hyperlipidemia (13-16) may have something to do, at 
least in part, with the berberine-regulated transcrip-
tion  of  hepatic  genes  involved  in  glucose  and  lipid 
metabolism.  The  berberine-mediated  AMPK  activa-
tion  may  contribute  in  part  to  its  effects  on  insu-
lin-regulated gene expression. Further understanding 
of the activation mechanism of berberine in hepato-
cytes may provide us with new tools to combat met-
abolic diseases. Int. J. Biol. Sci. 2011, 7 
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